Hi there.
I was diagnosed with hypothyroidism and a 4mm pituitary microadenoma 1 year ago.  I have been on Synthroid 100 and for the last year, I have taken .25 cabergoline 2x weekly.  
I just  had a followup MRI and to my shock, the tumor is now a "larger T2 hyperintense, T1 isointense 7x9x7 mm oval focus of decreased enhancement, with increased enhancement over dynamic imaging becoming relatively hyperintense compared to the adjacent pituitary gland consistant with a pituitary adenoma."  
Throughout this year, my prolactin was high, even though most of the labs stated that they were in the normal range.  My doctor informed me that because I have an adenoma, these ranges are not applicable to me.  What??? Now he tells me!  
So, now they want to double my dose of cabergoline to .5 2x weekly and then after 4 weeks test my Growth Hormones, to make sure I don't have a "chimera".  
Shouldn't they have tested that earlier?  Any information or guidance would be greatly appreciated! -Annette
                                                        
                                                     
                                                    
                                                        
                                                            
                                                            
                                                            
                                                                posted on
                                                            
                                                                Thu, 13 Mar 2014 
                                                            
                                                            
                                                            
                                                            
                                                                
                                                                    
                                                                    
                                                                    Thu, 19 Jan 2017
                                                                    
                                                                    
  Answered on 
                                                                 
                                                                
                                                                    
                                                                    
                                                                    Fri, 20 Jan 2017
                                                                    
                                                                    
  Last reviewed on